Reform and Prospect of Systemic Therapy on HER2-positive Early-stage Breast Cancer
10.3971/j.issn.1000-8578.2023.22.1521
- VernacularTitle:HER2阳性早期乳腺癌全身治疗变革及未来展望
- Author:
Guangyu LIU
1
;
Siyu WU
Author Information
1. Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China
- Publication Type:Research Article
- Keywords:
Early-stage breast cancer;
HER2-positive;
Systemic therapy;
Personalized treatment
- From:
Cancer Research on Prevention and Treatment
2023;50(5):437-441
- CountryChina
- Language:Chinese
-
Abstract:
In the past two decades, the survival of HER2-positive early-stage breast cancer patients has significantly improved with the development of HER2-targeted therapies. The focus has been placed on maximizing the clinical benefit of HER2-positive early-stage breast cancer by optimizing the treatment frameworks and therapeutic strategies in this field. In this paper, several important clinical studies of HER2-positive early-stage breast cancer in the neoadjuvant or adjuvant settings will be summarized and analyzed to provide clues for the development of personalized treatment strategies in the future.
